WuXi XDC Cayman Inc (HK: 2268), a China-based global CRDMO (Contract Research, Development, and Manufacturing Organisation) specialising in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), announced on Thursday that it has been recognised as the winner of the 'Best CDMO' at the World ADC Awards 2024.

The company is being honoured for the second consecutive year.

The firm has been recognised at the World ADC Awards for the past three years, including being named the winner of the 'Best CDMO' in 2023 and 'Best CMO Runner-up' in 2022. In 2024, the firm was also shortlisted for 'Best ADC Platform Technology' and 'Best CRO'.

Dr Jimmy Li, WuXi XDC CEO, said: "Winning the prestigious award at the World ADC is a tremendous honour for WuXi XDC and a reflection of our team's relentless dedication to innovation and excellence. The recognition underscores the significant trust our clients place in us. Receiving the winner of the 'Best CDMO' award for two consecutive years highlights the consistency of our efforts and our position as a global leader in the ADC industry. WuXi XDC's mission is to accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. We will strive to provide our clients with state-of-the-art technologies and integrated solutions to contribute to the global healthcare industry."